Claire Mazumdar, Ph.D.

Claire Mazumdar, Ph.D.

Chief Executive OfficeratBicara Therapeutics· In proxies 2023–2025

Pay in FY2025-90% from the year before · Bicara Therapeutics stock -3.4% the same year

Claire Mazumdar, Ph.D. was paid $927.7K in FY2025 (Dec), down 90%. Bicara Therapeutics stock fell 3.4% that year.

Pay$100 in the stock at the end of FY24 → $97
Pay is from the Summary Compensation Table of each Bicara Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Bicara TherapeuticsPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role -58%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?